• 1
    Bullingham RE, Nicholls A, Hale M. Pharmacokinetics of mycophenolate mofetil (RS61443): a short review. Transplant Proc 1996; 28: 9259.
  • 2
    Natsumeda Y, Ohno S, Kawasaki H, Konno Y, Weber G, Suzuki K. Two distinct cDNAs for human IMP dehydrogenase. J Biol Chem 1990; 265: 52925.
  • 3
    Collart FR, Huberman E. Cloning and sequence analysis of the human and Chinese hamster inosine-5′-monophosphate dehydrogenase cDNAs. J Biol Chem 1988; 263: 1576972.
  • 4
    Gu JJ, Stegmann S, Gathy K, Murray R, Laliberte J, Ayscue L, Mitchell BS. Inhibition of T lymphocyte activation in mice heterozygous for loss of the IMPDH II gene. J Clin Invest 2000; 106: 599606.
  • 5
    Gu JJ, Spychala J, Mitchell BS. Regulation of the human inosine monophosphate dehydrogenase type I gene. Utilization of alternative promoters. J Biol Chem 1997; 272: 445866.
  • 6
    Zimmerman AG, Sphycala J, Mitchell BS. Characterization of the human inosine-5′-monophosphate dehydrogenase type II gene. J Biol Chem 1995; 270: 680814.
  • 7
    Behrend M. Adverse gastrointestinal effects of mycophenolate mofetil: aetiology, incidence and management. Drug Saf 2001; 24: 64563.
  • 8
    Arns W. Noninfectious gastrointestinal (GI) complications of mycophenolic acid therapy: a consequence of local GI toxicity? Transplant Proc 2007; 39: 8893.
  • 9
    Knoll GA, MacDonald I, Khan A, Van Walraven C. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol 2003; 14: 23816.
  • 10
    Pelletier RP, Akin B, Henry ML, Bumgardner GL, Elkhammas EA, Rajab A, Ferguson RM. The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation. Clin Transplant 2003; 17: 2005.
  • 11
    Van Gelder T, Shaw LM. The rationale for and limitation of therapeutic drug monitoring for mycophenolate mofetil in transplantation. Transplantation 2005; 24453.
  • 12
    Burkhart C, Heusser C, Morris RE, Raulf F, Weckbecker G, Weitz-Schmidt G, Welzenbach K. Pharmacodynamics in the development of new immunosuppressive drugs. Ther Drug Monit 2004; 26: 58892.
  • 13
    Budde K, Glander P, Bauer S, Braun K, Waiser J, Fritsche L, Mai I, Roots I, Neumayer HH. Pharmacodynamic monitoring of mycophenolate mofetil. Clin Chem Lab Med 2000; 38: 12136.
  • 14
    Glander P, Hambach P, Braun KP, Fritsche L, Giessing M, Mai I, Einecke G, Waiser J, Neumayer HH, Budde K. Pre-transplant inosine monophosphate dehydrogenase activity is associated with clinical outcome after renal transplantation. Am J Transplant 2004; 4: 204551.
  • 15
    Kamar N, Glander P, Nolting J, Böhler T, Hambach P, Liefeldt L, Neumayer HH, Klupp J, Budde K. Effect of mycophenolate mofetil monotherapy on T-cell functions and inosine monophosphate dehydrogenase activity in patients undergoing a kidney transplantation. Transplant Proc 2006; 38: 22924.
  • 16
    Sanquer S, Breil M, Baron C, Dhamane D, Astier A, Lang P. Induction of inosine monophosphate dehydrogenase activity after long-term treatment with mycophenolate mofetil. Clin Pharmacol Ther 1999; 65: 6408.
  • 17
    Vethe NT, Mandla R, Line PD, Midtvedt K, Hartmann A, Bergan S. Inosine monophosphate dehydrogenase activity in renal allograft recipients during mycophenolate treatment. Scand J Clin Lab Invest 2006; 66: 3144.
  • 18
    Weigel G, Griesmacher A, Zuckermann AO, Laufer G, Mueller MM. Effect of mycophenolate mofetil therapy on inosine monophosphate dehydrogenase induction in red blood cells of heart transplant recipients. Clin Pharmacol Ther 2001; 69: 13744.
  • 19
    Bremer S, Mandla R, Vethe NT, Rasmussen I, Rootwelt H, Line PD, Midtvedt K, Bergan S. Expression of IMPDH1 and IMPDH2 after transplantation and initiation of immunosuppression. Transplantation 2008; 85: 5561.
  • 20
    Goldsmith D, Carrey EA, Edbury S, Smolenski RT, Jagodzinski P, Simmonds HA. Mycophenolate mofetil, an inhibitor of inosine monophosphate dehydrogenase, causes a paradoxical elevation of GTP in erythrocytes of renal transplant patients. Clin Sci 2004; 107: 638.
  • 21
    Racusen LC, Solez K, Colvin RB, Bonsib SM, Castro MC, Cavallo T, Croker BP, Demetris AJ, Drachenberg CB, Fogo AB, Furness P, Gaber LW, Gibson IW, Glotz D, Goldberg JC, Grande J, Halloran PF, Hansen HE, Hartley B, Hayry PJ, Hill CM, Hoffman EO, Hunsicker LG, Lindblad AS, Marcussen N, Mihatsch MJ, Nadasdy T, Nickerson P, Olsen TS, Papadimitriou JC, Randhawa PS, Rayner DC, Roberts I, Rose S, Rush D, Salinas-Madrigal L, Salomon DR, Sund S, Taskinen E, Trpkov K, Yamaguchi Y. The Banff97 working classification of renal allograft pathology. Kidney Int 1999; 55: 71323.
  • 22
    Solez K, Colvin RB, Racusen LC, Sis B, Halloran PF, Birk PE, Campbell PM, Cascalho M, Collins AB, Demetris AJ, Drachenberg CB, Gibson IW, Grimm PC, Haas M, Lerut E, Liapis H, Mannon RB, Marcus PB, Mengel M, Mihatsch MJ, Nankivell BJ, Nickeleit V, Papadimitriou JC, Platt JL, Randhawa P, Roberts I, Salinas-Madriga L, Salomon DR, Seron D, Sheaff M, Weening JJ. The Banff '05 Meeting report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy (CAN). Am J Transplant 2007; 7: 51826.
  • 23
    Pawinski T, Hale M, Korecka M, Fitzimmons WE, Shaw LM. Limited sampling strategy for the estimation of mycophenolic acid area under the curve in adult renal transplant patients treated with concomitant tacrolimus. Clin Chem 2002; 48: 1497504.
  • 24
    Van Hest RM, Mathôt RA, Vulto AG, Le Meur Y, Van Gelder T. Mycophenolic acid in diabetic renal transplant recipients. Pharmacokinetics and application of a limited sampling strategy. Ther Drug Monit 2004; 26: 6205.
  • 25
    De Loor H, Naesens M, Verbeke K, Vanrenterghem Y, Kuypers DR. Stability of mycophenolic acid and glucuronide metabolites in human plasma and the impact of deproteinization methodology. Clin Chim Acta 2008; 389: 8792.
  • 26
    Nowak I, Shaw LM. Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics. Clin Chem 1995; 41: 10117.
  • 27
    Shipkova M, Niedmann PD, Armstrong VW, Schütz E, Wieland E, Shaw LM, Oellerich M. Simultaneous determination of mycophenolic acid and its glucuronide in human plasma using a simple high-performance liquid chromatography procedure. Clin Chem 1998; 44: 14818.
  • 28
    Patel CG, Mendonza AE, Akhlaghi F, Majid O, Trull AK, Lee T, Holt DW. Determination of total mycophenolic acid and its glucuronide metabolite using liquid chromatography with ultraviolet detection and unbound mycophenolic acid using tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2004; 813: 28794.
  • 29
    Böyum A. Isolation of leucocytes from human blood. A two-phase system for removal of red cells with methylcellulose as erythrocyte-aggregating agent. Scand J Clin Lab Invest 1968; 97: 929.
  • 30
    Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 26575.
  • 31
    Glander P, Braun KP, Hambach P, Bauer S, Mai I, Roots I, Waiser J, Fritsche L, Neumayer HH, Budde K. Non-radioactive determination of inosine 5′-monophosphate dehydrogenase (IMPDH) in peripheral mononuclear cells. Clin Biochem 2001; 34: 5439.
  • 32
    Van Gelder T, Le Meur Y, Shaw LM, Oellerich M, DeNofrio D, Holt C, Holt DW, Kaplan B, Kuypers D, Meiser B, Toenshoff B, Mamelok RD. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit 2006; 28: 14554.
  • 33
    Le Meur Y, Büchler M, Thierry A, Caillard S, Villemain F, Lavaud S, Etienne I, Westeel PF, Hurault de Ligny B, Rostaing L, Thervet E, Szelag JC, Rérolle JP, Rousseau A, Touchard G, Marquet P. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant 2007; 7: 2496503.
  • 34
    Albrecht W, Storck M, Pfetsch E, Martin W, Abendroth D. Development and application of a high-performance liquid chromatography-based assay for determination of the activity of inosine 5′-monophosphate dehydrogenase in whole blood and isolated mononuclear cells. Ther Drug Monit 2000; 22: 28394.
  • 35
    Glander P, Sombogaard F, Budde K, Gelder TV, Hambach P, Liefeldt L, Lorkowski C, Mai M, Neumayer HH, Vulto AG, Mathot RA. Improved assay for the nonradioactive determination of inosine 5′-monophosphate dehydrogenase activity in peripheral blood mononuclear cells. Ther Drug Monit 2009; 31: 3519.
  • 36
    Budde K, Bauer S, Hambach P, Hahn U, Röblitz H, Mai I, Diekmann F, Neumayer HH, Glander P. Pharmacokinetic and pharmacodynamic comparison of enteric-coated mycophenolate sodium and mycophenolate mofetil in maintenance renal transplant patients. Am J Transplant 2007; 7: 88898.
  • 37
    Van Gelder T, Klupp J, Barten MJ, Christians U, Morris RE. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit 2001; 23: 11928.
  • 38
    Kobayashi M, Saitoh H, Kobayashi M, Tadano K, Takahashi Y, Hirano T. Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by Mrp2 in rats. J Pharmacol Exp Ther 2004; 309: 102935.
  • 39
    Shaw LM, Korecka M, Venkataramanan R, Golberg L, Bloom R, Brayman KL. Mycophenolic acid pharmacodynamic and pharmacokinetics provide a basis for rational monitoring strategies. Am J Transplant 2003; 3: 53442.
  • 40
    Shaw LM, Figurski M, Milone MC, Trofe J, Bloom RD. Therapeutic drug monitoring of mycophenolic acid. Clin J Am Soc Nephrol 2007; 2: 106272.
  • 41
    Sanquer S, Maison P, Tomkiewicz C, Macquin-Mavier I, Legendre C, Barouki R, Lang P. Expression of inosine monophosphate dehydrogenase type I and type II after mycophenolate mofetil treatment: a 2-year follow-up in kidney transplantation. Clin Pharmacol Ther 2008; 83: 32835.